Skip to content Skip to footer
Subscribe Now
NEWS

Pathos AI Inks ~2.2B Licensing Deal with Alphamab Oncology for JSKN016

Shots: Pathos AI has entered into a licensing agreement with Jiangsu Alphamab Biopharmaceuticals for JSKN016, a TROP2/HER3 bispecific ADC independently developed by Alphamab As per the deal, Pathos AI will receive exclusive rights to research, develop, manufacture & commercialize JSKN016 outside Greater China, funding all related costs, while Alphamab retains exclusive rights in mainland China,…
August 4, 2026

Read more

NEWS

Hansoh Pharma Reports P-III (ARTEMIS-011) Trial Data on Ris-Rez for Osteosarcoma

Shots: Hansoh has reported P-III (ARTEMIS-011) trial data assessing risvutatug rezetecan (HS-20093), a B7-H3–directed ADC, vs CT in pts with osteosarcoma who had progressed or relapsed after receiving ≥2 prior lines of systemic therapy Trial met its 1EP of improved PFS as assessed by the IRC, with consistent benefits observed across 2EPs, incl. OS & investigator-assessed…
July 28, 2026

Read more

Akesobio
NEWS

Akeso Reports First Patient Dosing in P-Ib/II Study of AK138D1 + Ivonescimab in NSCLC

Shots: Akeso has dosed the first patient in the P-Ib/II (AK138D1-201) trial assessing AK138D1, as monotx. or in combination with ivonescimab for advanced NSCLC The study will evaluate the regimen across multiple settings in advanced NSCLC, incl. 1L treatment, treatment after EGFR-TKI resistance, & treatment after immuno-CT resistance AK138D1 is a HER3-targeted ADC comprising a…
July 28, 2026

Read more

Innate Pharma
NEWS

Innate Pharma Completes Enrollment in P-I Dose Escalation Study of IPH4502

Shots: Innate Pharma completed enrollment in the P-I (IPH4502-101) dose-escalation study of IPH4502, its Nectin-4 exatecan ADC, enrolling 76 pts across France & the US, incl. those with UC, NSCLC, HNSCC, breast, ovarian, gastric, esophageal, & colorectal cancers Trial is evaluating the safety, tolerability, & preliminary antitumor activity of IPH4502 monotx. in advanced Nectin-4–expressing…
July 22, 2026

Read more

NEWS

Akari and Whitehawk Partner to Evaluate Dual-Payload ADC Approach

Shots: Akari has entered into a strategic research collaboration with Whitehawk to evaluate Akari’s PH1 spliceosome-modulating payload tech in combination with Whitehawk’s TOP1i ADC platform As per the deal, Akari will lead the design, execution, & evaluation of the research program, which will incl. multiple preclinical workstreams assessing dual-payload compatibility & potential synergies Collaboration begins…
July 21, 2026

Read more

NEWS

SystImmune Reports the NMPA Approval of Iza-bren to Treat Recurrent or Metastatic ESCC

Shots: The NMPA has approved iza-bren (izalontamab brengitecan) for the treatment of adult pts with recurrent or metastatic ESCC whose disease has progressed following prior Pt-based CT & PD-1/PD-L1 inhibitor therapy Approval was based on the P-III (PANKU-Esophagus01) trial assessing iza-bren vs CT in the above-mentioned pts (n=497) across China, which met its dual 1EP…
July 20, 2026

Read more

NEWS

Samsung Biologics to Acquire PolyPeptide for ~$1.8B

Shots: Samsung Biologics has launched an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide, expanding its capabilities beyond antibodies & ADCs to include peptide therapeutics As per the deal, PolyPeptide will receive CHF 44.31 (~$54.8) in cash per share, representing an implied equity value of ~CHF 1.46B (~$1.8B);…
July 20, 2026

Read more

NEWS

Hansoh Reports P-III (ARTEMIS-008) Trial Data on Risvutatug Rezetecan for Advanced or Relapsed SCLC

Shots: Hansoh has reported the P-III (ARTEMIS-008) trial results assessing risvutatug rezetecan (Ris-Rez/HS-20093) vs topotecan in pts with advanced or relapsed SCLC after prior Pt-based therapy Trial met its 1EP of improved OS in the interim analysis, with consistent benefit also observed across 2EPs, incl. PFS; data will be presented at an upcoming conference Based on…
July 10, 2026

Read more

NEWS

Biocytogen Collaborates with Whitehawk Therapeutics to Develop Bispecific ADC

Shots: Biocytogen has entered into a global collaboration with Whitehawk Therapeutics to develop bispecific antibody-drug conjugates (BsADCs) Biocytogen will provide ~5 bispecific antibodies from its RenLite platform & Whitehawk will evaluate these in combination with its ADC linker-payload technologies, with Whitehawk holding the option to advance resulting BsADC candidates Biocytogen will receive an upfront payment,…
July 8, 2026

Read more

Load more